Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. (2019)
Attributed to:
Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.bbmt.2018.09.001
PubMed Identifier: 30205231
Publication URI: http://europepmc.org/abstract/MED/30205231
Type: Journal Article/Review
Volume: 25
Parent Publication: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Issue: 2
ISSN: 1083-8791